title: Recent developments in texaphyrin chemistry and drug discovery.
abstract: Texaphyrins are pentaaza expanded porphyrins with the ability to form stable complexes with a variety of metal cations, particularly those of the lanthanide series. In biological milieus, texaphyrins act as redox mediators and mediate the production of reactive oxygen species (ROS). In this review, newer studies involving texaphyrin complexes targeting several different applications in anticancer therapy are described. In particular, the preparation of bismuth and lead texaphyrin complexes as potential α-core emitters for radiotherapy is detailed, as are gadolinium texaphyrin functionalized magnetic nanoparticles with features that make them of interest as dual-mode magnetic resonance imaging contrast agents and as constructs with anticancer activity mediated through ROS-induced sensitization and concurrent hyperthermia. Also discussed are gadolinium texaphyrin complexes as possible carrier systems for the targeted delivery of platinum payloads.
authors.affiliation: Department of Chemistry and Biochemistry, University of Texas , 1 University Station, A5300, Austin, Texas 78712-0165, United States.
authors.forename: Christian
authors.initials: C
authors.lastname: Preihs
authors.forename: Jonathan F
authors.initials: JF
authors.lastname: Arambula
authors.forename: Darren
authors.initials: D
authors.lastname: Magda
authors.forename: Heeyeong
authors.initials: H
authors.lastname: Jeong
authors.forename: Dongwon
authors.initials: D
authors.lastname: Yoo
authors.forename: Jinwoo
authors.initials: J
authors.lastname: Cheon
authors.forename: Zahid H
authors.initials: ZH
authors.lastname: Siddik
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Sessler
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology*; D001729:Bismuth / Q000737:chemistry*; D055808:Drug Discovery; D006801:Humans; D007854:Lead / Q000737:chemistry*; D008279:Magnetic Resonance Imaging / Q000379:methods; D058185:Magnetite Nanoparticles / Q000737:chemistry*; D017671:Platinum Compounds / Q000737:chemistry / Q000494:pharmacology; D011166:Porphyrins / Q000737:chemistry*
chemical_list: D000970:Antineoplastic Agents; D058185:Magnetite Nanoparticles; D017671:Platinum Compounds; D011166:Porphyrins; C442892:texaphyrin; D007854:Lead; D001729:Bismuth
references.citation: Clin Cancer Res. 1999 Apr;5(4):739-45
references.pmid: 10213207
references.citation: Proc Natl Acad Sci U S A. 1986 Jan;83(2):474-8
references.pmid: 3079913
references.citation: Biochem Pharmacol. 2012 Apr 15;83(8):1049-62
references.pmid: 22227014
references.citation: Dalton Trans. 2011 Jul 7;40(25):6591-609
references.pmid: 21384031
references.citation: Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):981-9
references.pmid: 10571206
references.citation: Radiology. 1999 Sep;212(3):755-9
references.pmid: 10478243
references.citation: Cell. 1997 Oct 31;91(3):325-34
references.pmid: 9363941
references.citation: Biochem Pharmacol. 2000 Apr 1;59(7):733-9
references.pmid: 10718331
references.citation: Chem Rev. 1997 Oct 1;97(6):2267-2340
references.pmid: 11848901
references.citation: Invest Radiol. 1994 Mar;29(3):330-8
references.pmid: 8175308
references.citation: Clin Cancer Res. 1999 Mar;5(3):655-63
references.pmid: 10100719
references.citation: Oncogene. 2003 Oct 20;22(47):7265-79
references.pmid: 14576837
references.citation: Chem Soc Rev. 2006 Jun;35(6):512-23
references.pmid: 16729145
references.citation: Angew Chem Int Ed Engl. 2007;46(27):5120-4
references.pmid: 17535004
references.citation: Angew Chem Int Ed Engl. 2012 Dec 7;51(50):12482-5
references.pmid: 23139178
references.citation: NMR Biomed. 2004 Nov;17(7):484-99
references.pmid: 15526347
references.citation: J Clin Oncol. 2002 Aug 15;20(16):3445-53
references.pmid: 12177105
references.citation: J Inorg Biochem. 1999 Oct;77(1-2):111-5
references.pmid: 10626362
references.citation: Medchemcomm. 2012;3(10):1275-1281
references.pmid: 23936624
references.citation: Expert Rev Med Devices. 2006 Jul;3(4):427-39
references.pmid: 16866640
references.citation: Chem Commun (Camb). 2010 Nov 14;46(42):7900-2
references.pmid: 20922235
references.citation: Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1069-76
references.pmid: 18977094
references.citation: J Inorg Biochem. 1999 Oct;77(1-2):65-70
references.pmid: 10626356
references.citation: Anticancer Agents Med Chem. 2011 Feb;11(2):222-32
references.pmid: 21355841
references.citation: Clin Cancer Res. 2008 Aug 1;14(15):4869-76
references.pmid: 18676760
references.citation: Cell. 2007 Mar 9;128(5):837-40
references.pmid: 17350571
references.citation: Chem Rev. 1999 Sep 8;99(9):2467-98
references.pmid: 11749487
references.citation: J Am Chem Soc. 2010 Aug 18;132(32):11015-7
references.pmid: 20698661
references.citation: Angew Chem Int Ed Engl. 2008;47(28):5122-35
references.pmid: 18574805
references.citation: Bioorg Med Chem Lett. 2011 Mar 15;21(6):1701-5
references.pmid: 21345675
references.citation: Gynecol Oncol. 2011 Aug;122(2):402-9
references.pmid: 21592546
references.citation: Dalton Trans. 2009 Dec 28;(48):10834-40
references.pmid: 20023913
references.citation: Oncogene. 1999 Nov 1;18(45):6145-57
references.pmid: 10557106
references.citation: Inorg Chem. 2006 Dec 25;45(26):10661-9
references.pmid: 17173421
references.citation: J Am Chem Soc. 2002 Jul 17;124(28):8416-27
references.pmid: 12105923
references.citation: Chem Rev. 2003 Mar;103(3):645-62
references.pmid: 12630848
references.citation: Q J Nucl Med Mol Imaging. 2004 Dec;48(4):289-96
references.pmid: 15640792